Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

(NasdaqGM:SGMT), Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announced completion of its pre-NDA consultation with China's NMPA and its plans to submit an NDA for denifanstat in China SAN MATEO, Calif., Oct. […]

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

(NASDAQ:GLUE), MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model Data support the potential of MRT-6160 to address multiple rheumatic autoimmune and inflammatory diseases, including Sjogren's disease, systemic lupus erythematosus, and rheumatoid arthritis Poster presentation on October 26th at 10:30 am CDT BOSTON,

Caliber to Sponsor & Attend Chainlink’s 2025 SmartCon Conference

(NASDAQ:CWD), SCOTTSDALE, Ariz., Oct. 24, 2025 (GLOBE NEWSWIRE) — Caliber (NASDAQ: CWD), a diversified real estate and digital asset management platform, today announced that it will be sponsoring the 2025 SmartCon Conference at the Metropolitan Pavilion in New York City on November 4-5, 2025. Caliber will join notable finance sponsors Fidelity Investments, Swift, S&P Global,

GURU Organic Energy Continues Its Record-Breaking Streak on Amazon Prime Days in October

(TSX:GURU), MONTRÉAL, Oct. 24, 2025 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company“), Canada's leading organic energy drink brand1, is proud to announce its solid performance during Amazon's October Prime Big Deal Days event, with the Company significantly outperforming the overall energy drink category in both markets. GURU continued to

Green Thumb Industries to Report Third Quarter 2025 Financial Results on November 5, 2025

(CNSX:GTII.CN),(OTC US:GTBIF),(Other OTC:GTBIF), CHICAGO and VANCOUVER, British Columbia, Oct. 24, 2025 (GLOBE NEWSWIRE) — Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced it will release third quarter 2025 financial results after the market closes on Wednesday, November 5,

Pasinex Closes Over-Subscribed Non-Brokered Private Placement

(CNSX:PSE.CN),(Boerse Frankfurt – Freiverkehr:PNX),(CNSX:PSE), TORONTO, Oct. 24, 2025 (GLOBE NEWSWIRE) — Pasinex Resources Limited (CSE: PSE; FSE: PNX) (“Pasinex” or the “Company“) is pleased to announce that it has closed its non brokered private placement of common shares for gross proceeds of C$ 2,331,540 (the “Offering“), previously announced on July 15, 2025. Offering Details Securities

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

(NYSE MKT:CATX), SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 10, 2025 after the

ECARX Antora(R) and Cloupeak(R) Solutions Expand into UK with Launch of Geely EX5

(NasdaqGM:ECX), LONDON, Oct. 24, 2025 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility technology provider, today announced that its AI Enhanced Antora(R) 1000 computing platform and Cloudpeak(R) cross-domain software stack will drive the launch of Geely Galaxy EX5 in the United Kingdom themed “Intelligent Everyday”. This marks the

General Dynamics Reports Third-Quarter 2025 Financial Results

— Revenue $12.9 billion, up 10.6% from year-ago quarter — Diluted EPS $3.88, up 15.8% from year-ago quarter — $2.1 billion cash from operating activities, 199% of net earnings — Very strong order activity in all four segments General Dynamics (NYSE: GD) today reported third-quarter 2025 operating earnings of $1.3 billion, or $3.88 per diluted

Scroll to Top